Diagnostic Utility of CXCL13 in Lyme Neuroborreliosis
Authors:
- 28 March 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 72 (10) , 1727-1729
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- CXCL13 concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other neurological disorders determined by Luminex and ELISATicks and Tick-borne Diseases, 2018
- Neuroimmunomodulators in Neuroborreliosis and Lyme EncephalopathyClinical Infectious Diseases, 2018
- CXCL13 as a diagnostic marker of neuroborreliosis and other neuroinflammatory disorders in an unselected group of patientsJournal of Neurology, 2017
- Lyme borreliosisNature Reviews Disease Primers, 2016
- Course and Outcome of Early European Lyme Neuroborreliosis (Bannwarth Syndrome): Clinical and Laboratory FindingsClinical Infectious Diseases, 2016
- CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammationJournal of Neuroinflammation, 2014
- CXCL13 may improve diagnosis in early neuroborreliosis with atypical laboratory findingsBMC Infectious Diseases, 2012
- Lyme borreliosisThe Lancet, 2012
- EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosisEuropean Journal of Neurology, 2009
- CSF B – lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosisJournal of Neurology, 2008